ヘルスケア
ヘルスケアは、グローバルトレンド、技術・革新及び各国の市場特性、人口動態や規制当局に影響を受けるセクターです。
アジアにおける投資及び業界再編に影響を与える主な要因は:
- 可処分所得の増加、急速に変化する多様な人口動態;
- 地理的及び生理学的な特性;
- 政府・行政支援による医療システムの発展;
- メディカル及びライフサイエンステクノロジーに精通するイノベーターの出現;
- グローバル投資家のアジア成長市場への活発な参入、アジア企業による旺盛な域内及び海外M&A意欲
BDAのグローバルヘルスケアチームは、アジア各国の事情に即した深い知見・洞察力、グローバルな視点及び豊富な案件実績により各種事業会社、フィナンシャルスポンサー、起業家などのクライアントに対してフィナンシャルアドバイザリーサービスを提供しています。これまで、ヘルスケアサービス、医療技術、製薬、バイオテクノロジー、外部委託製薬サービス(CRO・CDMO)、コンシューマーヘルス、農動植物ライフサイエンスに対するフィナンシャルアドバイザリー実績を有しています。
Andrew Huntley
Managing Partner, Head of Healthcare
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
LAP Lasers a portfolio company of
has been acquired by
2019
divested majority stake to
2019
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
recapitalized majority by
2017
divested CMC Biologics to
2017
has been acquired by a Japanese chemicals & life science company
2016
acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013
divested Radiant Research Inc, US-based clinical research company
2012
divested medical supply business to
2012
established an animal vaccine JV with Jilin Guoyuan Animal Health
2011